Abbott Laboratories vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Abbott Laboratories trades at $109.8 (market cap $187.95B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.91. The key difference: Abbott Laboratories pays a 2.32% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | PDBC | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $18.91 |
52-Week Low | $82.57 | $12.90 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
PDBC, an ETF tracking diversified commodities, trades at $17.25, up 0.12% with a bearish technical signal. Recent news highlights institutional inflows, such as Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (Defense World, 2026-07-19), and a Seeking Alpha downgrade to hold due to weakening commodity momentum (2026-06-11). The ETF has outperformed the S&P 500 by nearly 10 percentage points since March 2024 but faces headwinds from oil price declines and geopolitical tensions.
Outlook is mixed: commodities offer inflation hedging potential, with PDBC surging 50% amid supply disruptions (24/7 Wall Street, 2026-05-11), but risks include a potential 'super-squeeze' from Middle East conflicts (HSBC via 24/7 Wall Street, 2026-07-24) and tax-related complexities. Investors should weigh diversification benefits against volatile commodity cycles and roll costs.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →